RxDoctor Payments Data

Terrence Grimm, MD

Urology · Lexington, KYNPI 1740286822

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,217 of the $8,575 with a category attached, or 72.5%. It is spread thinly across 41 manufacturers, the largest accounting for just 20.1%. 2025 is the largest year on record at $2,516, 4.0 times the $633 reported in 2019.

$8,575in general payments, 2019–2025

Across 217 payments — averaging $39.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$2K
  • Medtronic$1K
  • Procept Biorobotics Corporation$1K
  • Sumitomo Pharma America, Inc.$628
  • Astellas Pharma US Inc$391
  • Neotract Inc.$384
  • plus $3K from 35 others

What the payments were for

  • Travel & lodging$2,15725%
  • Food & beverage$6,21773%
  • Education$2022%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,575 in reported general payments places this provider in the 80th percentile of 139 urology providers in Kentucky.

See all urology providers in Kentucky

Medicare billing

Part B allowed, 2024
$183,750
Medicare patients
729
Services billed
17,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nilutamide12$56,789
MyrbetriqMirabegron87$50,715
GemtesaVibegron80$49,171
Mirabegron ErMirabegron17$12,551
Testosterone71$9,602
Tamsulosin Hcl618$6,368
Tolterodine Tartrate ErTolterodine Tartrate69$5,354
Dutasteride222$4,947
Trimethoprim64$4,555
Methenamine Hippurate63$4,454
Solifenacin Succinate90$3,866
Oxybutynin Chloride ErOxybutynin Chloride117$3,720
Desmopressin Acetate29$3,063
Finasteride224$2,794
Potassium Citrate ErPotassium Citrate32$2,379

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$391$50,71587 claims
Sumitomo Pharma America, Inc.Gemtesa$628$49,17180 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 139 urology providers in Kentucky.

Other urology in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →